TORONTO, Sept. 11 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX: ARI) today
announced that Dr. David Young, President and CSO of ARIUS has been invited to
speak about ARIUS and its business model during Bio Week 2006 in Japan.
"Our participation at Bio Japan in 2004 lead to our successful
collaboration with Takeda Pharmaceuticals, one of the largest Japanese
Pharmaceutical Companies," said Dr. David S. Young, President and Chief
Scientific Officer of ARIUS, "We look forward to the 2006 opportunity to meet
with partners in this important market and increase the exposure of ARIUS. We
are working to build value into our preclinical candidates and are seeking
clinical collaborations to take the next step and begin the process of helping
cancer patients."
ARIUS will be one of the presenting companies in an event organized by
the Canadian Embassy in Tokyo on September 11, 2006 at 2:00 pm. ARIUS will
also participate in BioJapan and the JETRO BioLink Forum 2006 in Osaka from
September 13-15 2006. ARIUS will describe recent developments from its
anticancer antibody FunctionFIRST(TM) platform and available partnering
candidates. In addition, ARIUS will participate in a panel at the Canada-Japan
Science and Technology 20th Anniversary Symposium: "Bringing Science to Life
through Commercialization" in Tokyo on September 13, 2006.
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
